GlassScriptPhysician profile
Steven I Goodman
NPI 1447351184
$15,959.45
in general payments reported to CMS, 2019-2025
44 companies · $2,845 in 2025
The $2,845 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,242 · 2020: $1,503 · 2021: $2,245 · 2022: $2,061 · 2023: $2,433 · 2024: $2,631 · 2025: $2,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,867 · Education: $42.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,867.04 |
| Education | $42.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,223.96 | 2019-2025 | Evenity, Prolia, Enbrel |
| Abbvie INC. | $1,684.46 | 2019-2025 | |
| Ucb, INC. | $1,473.94 | 2020-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,343.64 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $1,343.24 | 2019-2025 | |
| Pfizer INC. | $1,060.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $959.17 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $744.47 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.16 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Radius Health, INC. | $634.45 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $577.68 | 2021-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $543.51 | 2020-2025 | Acthar |
| Genentech USA, INC. | $348.85 | 2019-2025 | Gazyva, Actemra, Rituxan |
| Sobi, INC | $272.60 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $185.77 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.